Traders Purchase High Volume of Call Options on Chemours (NYSE:CC)

The Chemours Company (NYSE:CC) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 21,465 call options on the company. This is an increase of approximately 633% compared to the typical daily volume of 2,930 call options.

Chemours Price Performance

Shares of Chemours stock opened at $13.34 on Friday. Chemours has a 52-week low of $10.44 and a 52-week high of $28.67. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -13.08 and a beta of 1.47. The company has a fifty day moving average of $13.80 and a 200-day moving average of $18.17. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.98 and a current ratio of 1.81.

Chemours (NYSE:CC) last issued its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.53 billion. Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. Chemours’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.40 EPS. Equities research analysts expect that Chemours will post 0.82 EPS for the current year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be issued a $0.0875 dividend. The ex-dividend date is Monday, November 16th. This represents a $0.35 annualized dividend and a dividend yield of 2.6%. Chemours’s payout ratio is currently -34.31%.

Analysts Set New Price Targets

Several brokerages recently issued reports on CC. JPMorgan Chase & Co. cut their target price on shares of Chemours from $15.00 to $14.00 and set a “neutral” rating for the company in a research report on Monday. Royal Bank Of Canada downgraded Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target on the stock. in a research report on Tuesday, October 13th. Morgan Stanley set a $18.00 price target on Chemours in a research report on Monday, August 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $16.00 price target on shares of Chemours in a research note on Friday, October 9th. Finally, Barclays started coverage on Chemours in a report on Monday, October 12th. They issued an “equal weight” rating and a $16.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $17.36.

Institutional Investors Weigh In On Chemours

Several institutional investors have recently bought and sold shares of CC. Parallel Advisors LLC increased its stake in Chemours by 10.9% in the 1st quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock worth $118,000 after purchasing an additional 527 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Chemours during the second quarter valued at approximately $34,000. Allworth Financial LP purchased a new stake in shares of Chemours during the second quarter valued at approximately $51,000. State of Wyoming bought a new position in shares of Chemours in the second quarter worth approximately $67,000. Finally, Corient Private Wealth LP grew its holdings in shares of Chemours by 12.6% in the second quarter. Corient Private Wealth LP now owns 30,644 shares of the specialty chemicals company’s stock worth $629,000 after purchasing an additional 3,432 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Latest Chemours News

Here’s some of the latest news about CC:

• Neutral Sentiment: Unusually high call-option activity was reported on November 11: investors bought 21,465 calls, about 7.3 times the average daily volume. This may reflect bullish speculation, but by itself does not establish a positive outlook for the shares.
• Negative Sentiment: Several law firms publicized a securities class action against Chemours and certain officers. The complaint alleges the company overstated demand in the Opteon refrigerant aftermarket: record 2025 sales allegedly reflected an overstocked distribution channel that contributed to a weaker 2026 outlook. These are allegations, not findings; investors who bought shares from February 20 through August 4, 2026, have until December 7 to seek lead-plaintiff status. The legal overhang adds uncertainty and follows a reported 18.63% share-price decline. Read the article
• Negative Sentiment: A separate report says JPMorgan issued a pessimistic forecast for CC, adding to the negative analyst sentiment, though the supplied item provides no details on the forecast or its reasoning. Read the article

Chemours Company Profile

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.